Neil Anthony Pegg

Title: Neil Anthony Pegg: Innovator in Pharmaceutical Compounds

Introduction

Neil Anthony Pegg is a notable inventor based in Slough, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific diseases and disorders. With a total of 5 patents to his name, Pegg's work has the potential to impact various medical conditions.

Latest Patents

Pegg's latest patents focus on pharmaceutical compounds known as thienopyrimidines. These compounds are designed to act as inhibitors of PI3K, specifically targeting the p110 delta subtype. This inhibition may be beneficial in treating a range of diseases and disorders associated with abnormal cell growth and function, including immune disorders, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine disorders, and neurological disorders. Additionally, the patents describe processes for synthesizing these compounds, further enhancing their applicability in medical treatments.

Career Highlights

Throughout his career, Neil Anthony Pegg has worked with prominent companies in the pharmaceutical industry, including F. Hoffmann-La Roche AG and Genentech, Inc. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Pegg has collaborated with notable colleagues such as Timothy Colin Hancox and Stephen Colin Price. These partnerships have likely enriched his research and development efforts, leading to advancements in the pharmaceutical field.

Conclusion

Neil Anthony Pegg's contributions to pharmaceutical innovations, particularly in the area of PI3K inhibitors, demonstrate his commitment to addressing critical health challenges. His work continues to pave the way for potential treatments that could improve patient outcomes in various medical conditions.